TY - JOUR
T1 - Clinical potential of proteomics in the diagnosis of ovarian cancer
AU - Ardekani, Ali M.
AU - Liotta, Lance A.
AU - Petricoin, Emanuel F.
N1 - Funding Information:
Lance A Liotta, MD, PhD Codirector FDA-NCI Clinical Proteomics Program NCI-FDA Clinical Proteomics Program Center for Biologics Evaluation and Research, Food and Drug Administration and Laboratory of Pathology, Center for Cancer Research, National Cancer Institute and Bethesda, MD 20892, USA Emmanuel F Petricoin III, PhD Codirector FDA-NCI Clinical Proteomics Program Proteomics Unit Building 29A/Room 2A-21 Bethesda, MD 20892, USA Tel.: +1 301 827 1753 Fax: +1 301 480 3256 [email protected] Ali M Ardekani Staff Scientist Proteomics Unit Building 29A/Room 2A-21 Bethesda, MD 20892, USA
PY - 2002
Y1 - 2002
N2 - The need for specific and sensitive markers of ovarian cancer is critical. Finding a sensitive and specific test for its detection has an important public health impact. Currently, there are no effective screening options available for patients with ovarian cancer. CA-125, the most widely used biomarker for ovarian cancer, does not have a high positive predictive value and it is only effective when used in combination with other diagnostic tests. However, pathologic changes taking place within the ovary may be reflected in biomarker patterns in the serum. Combination of mass spectra generated by new proteomic technologies, such as surface-enhanced laser desorption ionization time-of-flight (SELDI-TOF) and artificial-intelligence-based informatic algorithms, have been used to discover a small set of key protein values and discriminate normal from ovarian cancer patients. Serum proteomic pattern analysis might be applied ultimately in medical screening clinics, as a supplement to the diagnostic work-up and evaluation.
AB - The need for specific and sensitive markers of ovarian cancer is critical. Finding a sensitive and specific test for its detection has an important public health impact. Currently, there are no effective screening options available for patients with ovarian cancer. CA-125, the most widely used biomarker for ovarian cancer, does not have a high positive predictive value and it is only effective when used in combination with other diagnostic tests. However, pathologic changes taking place within the ovary may be reflected in biomarker patterns in the serum. Combination of mass spectra generated by new proteomic technologies, such as surface-enhanced laser desorption ionization time-of-flight (SELDI-TOF) and artificial-intelligence-based informatic algorithms, have been used to discover a small set of key protein values and discriminate normal from ovarian cancer patients. Serum proteomic pattern analysis might be applied ultimately in medical screening clinics, as a supplement to the diagnostic work-up and evaluation.
KW - Diagnostics
KW - Ovarian cancer
KW - Proteomics
UR - http://www.scopus.com/inward/record.url?scp=0036020072&partnerID=8YFLogxK
U2 - 10.1586/14737159.2.4.312
DO - 10.1586/14737159.2.4.312
M3 - Review article
C2 - 12138495
AN - SCOPUS:0036020072
SN - 1473-7140
VL - 2
SP - 312
EP - 320
JO - Expert Review of Molecular Diagnostics
JF - Expert Review of Molecular Diagnostics
IS - 4
ER -